The phase III DUO trial of PI3K inhibitor duvelisib <i>versus</i> ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival

Alexey V. Danilov; Ian W. Flinn; Matthew S. Davids; Beth Gregory; Ohad Bentur; David Sidransky; Jennifer R. Brown

doi:10.3324/haematol.2024.285043

Open access journal of the Ferrata-Storti Foundation, a non-profit organization

Letters to the Editor

The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival

Alexey V. Danilov
Ian W. Flinn
Matthew S. Davids
Beth Gregory
Ohad Bentur
David Sidransky
Jennifer R. Brown

City of Hope National Medical Center, Duarte, CA

Tennessee Oncology, Nashville, TN

CLL Center, Dana-Farber Cancer Institute, Boston, MA

Secura Bio, Inc., Las Vegas, NV

Johns Hopkins University, Baltimore, MD

CLL Center, Dana-Farber Cancer Institute, Boston, MA

Haematologica Early view May 30, 2024 https://doi.org/10.3324/haematol.2024.285043

Data Supplements

Supplementary Appendix

Figures & Tables

Article Information

Early view : Letters to the Editor

DOI

https://doi.org/10.3324/haematol.2024.285043

Pubmed

38813715

Published

2024-05-30

Published By

Ferrata Storti Foundation, Pavia, Italy

Print ISSN

0390-6078

Online ISSN

1592-8721

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views

521

PDF Downloads

241

Statistics from Altmetric.com

No Data

The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival

Data Supplements

Figures & Tables

Article Information

Article Usage

Statistics from Altmetric.com

Download Citation

Navigate

For Authors

For Reviewers

For Advertisers

Education

Privacy

More